

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:

LOGINID: ssspta1600dxk

STN INTERNATIONAL LOGOFF AT 11:38:55 ON 30 JAN 2002

Connection closed by remote host

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID: ssspta1600dxk

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * Welcome to STN International * * * * * * * * * * *

| | | |
|--------------|----|---|
| NEWS | 1 | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | Sep 17 IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH |
| NEWS | 3 | Oct 09 Korean abstracts now included in Derwent World Patents Index |
| NEWS | 4 | Oct 09 Number of Derwent World Patents Index updates increased |
| NEWS | 5 | Oct 15 Calculated properties now in the REGISTRY/ZREGISTRY File |
| NEWS | 6 | Oct 22 Over 1 million reactions added to CASREACT |
| NEWS | 7 | Oct 22 DGENE GETSIM has been improved |
| NEWS | 8 | Oct 29 AAASD no longer available |
| NEWS | 9 | Nov 19 New Search Capabilities USPATFULL and USPAT2 |
| NEWS | 10 | Nov 19 TOXCENTER(SM) - new toxicology file now available on STN |
| NEWS | 11 | Nov 29 COPPERLIT now available on STN |
| NEWS | 12 | Nov 29 DWPI revisions to NTIS and US Provisional Numbers |
| NEWS | 13 | Nov 30 Files VETU and VETB to have open access |
| NEWS | 14 | Dec 10 WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002 |
| NEWS | 15 | Dec 10 DGENE BLAST Homology Search |
| NEWS | 16 | Dec 17 WELDASEARCH now available on STN |
| NEWS | 17 | Dec 17 STANDARDS now available on STN |
| NEWS | 18 | Dec 17 New fields for DPCI |
| NEWS | 19 | Dec 19 CAS Roles modified |
| NEWS | 20 | Dec 19 1907-1946 data and page images added to CA and CPlus |
| NEWS | 21 | Jan 25 BLAST(R) searching in REGISTRY available in STN on the Web |
| NEWS | 22 | Jan 25 Searching with the P indicator for Preparations |
| NEWS | 23 | Jan 29 FSTA has been reloaded and moves to weekly updates |
| NEWS EXPRESS | | August 15 CURRENT WINDOWS VERSION IS V6.0c,
CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP),
AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001 |
| NEWS HOURS | | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | | General Internet Information |
| NEWS LOGIN | | Welcome Banner and News Items |
| NEWS PHONE | | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:39:36 ON 30 JAN 2002

=> file caplus
COMMAND INTERRUPTED
SESSION CONTINUES IN FILE 'HOME'
If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help
Desk by telephone or via SEND in the STNMAIL file.

FILE 'BIOSIS' ENTERED AT 11:41:00 ON 30 JAN 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNS) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 24 January 2002 (20020124/ED)

The BIOSIS file has been reloaded. Enter HELP RLOAD and HELP REINDEXING for details.

=> s doxorubicin?
L1 16427 DOXORUBICIN?

=> s 11 and taxanes?
617 TAXANES?
I-2 64 L1 AND TAXANES?

=> s 12 and anti-cancer?
418620 ANTI
13 ANTIS
418628 ANTI
(ANTI OR ANTIS)
395961 CANCER?
4274 ANTI-CANCER?
(ANTI (W) CANCER?)
L4 1 L2 AND ANTI-CANCER?

=> d 14 abs ibib

L4 ANSWER 1 OF 1 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AB The chimeric monoclonal antibody cBR96 conjugated to doxorubicin (cBR96-Dox) is selectively internalized by a wide variety of human carcinomas expressing an extended form of Lewis Y antigen (Ley). Endocytosis is followed by cleavage and release of free doxorubicin from the endocytic vesicles and subsequent cytotoxicity. Combination studies with standard anti-cancer agents, undertaken to further increase the potency of this targeted therapy, identified significant synergistic anti-tumor activity of cBR96-Dox and either of the taxanes paclitaxel or docetaxel. Treatment with cBR96-Dox 24 hr prior to paclitaxel resulted in a steady increase in the percentage of G2 tumor cells and corresponding increase in sensitivity to taxanes. Cell cycle analysis indicated the cBR96-delivered doxorubicin was most effective against S-phase cells, yet cells exposed to even subtoxic levels progressed to and arrested in G2, at a point of high sensitivity to the anti-tubulin agent paclitaxel. The synergy obtained by staged combination of cBR96-Dox and paclitaxel in vitro was reflected in significant anti-tumor efficacy in vivo against xenograft models of human lung and breast tumors that could not be achieved by either agent alone. The staged combination elicited significant or complete regressions of established human Ley-positive tumor xenografts using significantly reduced drug levels. Taken together, these data demonstrate a mechanistic approach to the selective elimination of Ley-positive tumors by using targeted doxorubicin followed by taxane treatment.

ACCESSION NUMBER: 2001:417196 BIOSIS
DOCUMENT NUMBER: PREV200100417196
TITLE: Selective tumor sensitization to taxanes with the mab-drug conjugate CBR96-doxorubicin.
AUTHOR(S): Wahl, Alan F. (1); Donaldson, Karen L.; Mixan, Bruce J.; Trail, Pamela A.; Siegall, Clay B.
CORPORATE SOURCE: (1) Seattle Genetics, Inc., 22215 26th Ave. SE, Bothell, WA, 98021: awahl@seagen.com USA
SOURCE: International Journal of Cancer, (15 August, 2001) Vol. 93,
No. 4, pp. 590-600. print.
ISSN: 0020-7136.
DOCUMENT TYPE: Article
LANGUAGE: English
SUMMARY LANGUAGE: English

=> d 12 1-30

L2 ANSWER 1 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2002:26135 BIOSIS
DN PREV200200026135
TI Dose scheduling-Herceptin(R).
AU Leyland-Jones, Brian (1)
CS (1) Department of Oncology, McGill University, 3655 Drummond Avenue, Suite 701, Montreal, PQ, H3G 1Y6: leylandj@med.mcgill.ca Canada
SO Oncology (Basel), (October, 2001) Vol. 61, No. Suppl 2, pp. 31-36.
print.
ISSN: 0030-2414.

DT Article
LA English

L2 ANSWER 2 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2002:21868 BIOSIS
DN PREV200200021868
TI Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel.
AU Taghian, Alphonse G. (1); Assaad, Sherif I.; Niemierko, Andrzej; Kuter, Irene; Younger, Jerry; Schoenthaler, Robin; Roche, Maria; Powell, Simon
N.
CS (1) Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom St., Cox 3, Boston, MA, 02114:
ataghian@partners.org USA
SO Journal of the National Cancer Institute (Bethesda), (December 5, 2001) Vol. 93, No. 23, pp. 1806-1811. print.
ISSN: 0027-8874.

DT Article
LA English

L2 ANSWER 3 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:545353 BIOSIS
DN PREV200100545353
TI A pitfall in the survival benefit of adjuvant chemotherapy for node- and hormone receptor-positive patients with breast cancer: The paradoxical role of Bcl-2 oncoprotein (Review).
AU Kim, Ryungsa (1); Osaki, Akihiko; Toge, Tetsuya
CS (1) Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553: rkim@ipc.hiroshima-u.ac.jp Japan
SO International Journal of Oncology, (November, 2001) Vol. 19, No. 5, pp. 1075-1080. print.
ISSN: 1019-6439.

DT General Review
LA English
SL English

L2 ANSWER 4 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:476692 BIOSIS
DN PREV200100476692
TI Epirubicin in combination with the taxanes.
AU Trudeau, Maureen (1); Pagani, Olivia
CS (1) Toronto Sunnybrook Regional Cancer Centre, 2075 Bayview Ave, Toronto, ON, M4N-5L4 Canada
SO Seminars in Oncology, (August, 2001) Vol. 28, No. 4 Suppl 12, pp. 41-50. print.
ISSN: 0093-7754.

DT Article
LA English
SL English

L2 ANSWER 5 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:476688 BIOSIS
DN PREV200100476688
TI Pharmacokinetic profiles of doxorubicin in combination with taxanes.
AU Holmes, Frankie Ann (1); Rowinsky, Eric Keith
CS (1) 909 Frostwood Dr, No. 221, Houston, TX, 77024-2305 USA
SO Seminars in Oncology, (August, 2001) Vol. 28, No. 4 Suppl 12, pp. 8-14. print.

ISSN: 0093-7754.

DT Article

LA English

SL English

L2 ANSWER 6 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2001:466214 BIOSIS

DN PREV200100466214

TI Drug interactions with the taxanes: Clinical implications.

AU Baker, A. F. (1); Dorr, R. T.

CS (1) Arizona Cancer Center, 1515 N Campbell Avenue, Tucson, AZ,
85724-5024:

abaker@azcc.arizona.edu USA

SO Cancer Treatment Reviews, (August, 2001) Vol. 27, No. 4, pp. 221-233.
print.

ISSN: 0305-7372.

DT General Review

LA English

SL English

L2 ANSWER 7 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2001:425850 BIOSIS

DN PREV200100425850

TI Effects of orally active taxanes on P-glycoprotein modulation
and colon and breast carcinoma drug resistance.

AU Vredenburg, Michael R.; Ojima, Iwao; Veith, Jean; Pera, Paula; Kee,
Kristin; Cabral, Fernando; Sharma, Amarnath; Kanter, Peter; Greco,
William

R.; Bernacki, Ralph J. (1)

CS (1) Department of Pharmacology and Therapeutics, Roswell Park Cancer
Institute, Elm and Carlton Sts., Buffalo, NY, 14263:
Ralph.Bernacki@roswellpark.org USA

SO Journal of the National Cancer Institute (Bethesda), (August 15, 2001)
Vol. 93, No. 16, pp. 1234-1245. print.

ISSN: 0027-8874.

DT Article

LA English

SL English

L2 ANSWER 8 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2001:419077 BIOSIS

DN PREV200100419077

TI Resistance to topoisomerase poisons due to loss of DNA mismatch repair.

AU Fedier, Andre; Schwarz, Viola A.; Walt, Heinrich; Carpini, Renato Delli;
Haller, Urs; Fink, Daniel (1)

CS (1) Department of Obstetrics and Gynecology, University of Zurich,
CH-8091, Zurich: daniel.fink@fhk.usz.ch Switzerland

SO International Journal of Cancer, (15 August, 2001) Vol. 93, No. 4, pp.
571-576. print.

ISSN: 0020-7136.

DT Article

LA English

SL English

L2 ANSWER 9 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2001:417518 BIOSIS

DN PREV200100417518

TI Optimal adjuvant cytotoxic therapy for breast cancer.

AU Lohrisch, C.; Di Leo, A.; Piccart, M. J. (1)

CS (1) Jules Bordet Institute, 1 Rue Heger-Bordet, B-1000, Brussels:

mpiccart@ulb.ac.be Belgium
SO Breast, (August, 2001) Vol. 10, No. Supplement 3, pp. 106-113. print.
ISSN: 0960-9776.
DT General Review
LA English
SL English

L2 ANSWER 10 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:417515 BIOSIS
DN PREV200100417515
TI The use of anthracyclines and taxanes for adjuvant therapy of breast cancer.
AU Davidson, N. E. (1); Wolff, A. C.
CS (1) Johns Hopkins Oncology Center, 1650 Orleans Street, Room 409, Baltimore, MD, 21231-1000 USA
SO Breast, (August, 2001) Vol. 10, No. Supplement 3, pp. 90-95. print.
ISSN: 0960-9776.
DT General Review
LA English
SL English

L2 ANSWER 11 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:417196 BIOSIS
DN PREV200100417196
TI Selective tumor sensitization to taxanes with the mab-drug conjugate CBR96-doxorubicin.
AU Wahl, Alan F. (1); Donaldson, Karen L.; Mixan, Bruce J.; Trail, Pamela A.; Siegall, Clay B.
CS (1) Seattle Genetics, Inc., 22215 26th Ave. SE, Bothell, WA, 98021: awahl@seagen.com USA
SO International Journal of Cancer, (15 August, 2001) Vol. 93, No. 4, pp. 590-600. print.
ISSN: 0020-7136.
DT Article
LA English
SL English

L2 ANSWER 12 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:306194 BIOSIS
DN PREV200100306194
TI Use of paclitaxel in patients with pre-existing cardiomyopathy: A review of our experience.
AU Gollerkeri, Ashwin; Harrold, Laurie; Rose, Michal; Jain, Diwaker; Burtness, Barbara Ann (1)
CS (1) Yale University School of Medicine, 333 Cedar Street, New Haven, CT, 06520: barbara.burtness@yale.edu USA
SO International Journal of Cancer, (1 July, 2001) Vol. 93, No. 1, pp. 139-141. print.
ISSN: 0020-7136.
DT Article
LA English
SL English

L2 ANSWER 13 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:294479 BIOSIS
DN PREV200100294479
TI Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
AU Burstein, Harold J.; Kuter, Irene; Campos, Susana M.; Gelman, Rebecca S.;

Tribou, Laura; Parker, Leroy M.; Manola, Judith; Younger, Jerry;
Matulonis, Ursula; Bunnell, Craig A.; Partridge, Ann H.; Richardson, Paul
G.; Clarke, Kathryn; Shulman, Lawrence N.; Winer, Eric P. (1)
CS (1) Dana-Farber Cancer Institute, 44 Binney St, Boston, MA, 02115:
ewiner@partners.org USA

SO Journal of Clinical Oncology, (May 15, 2001) Vol. 19, No. 10, pp.
2722-2730. print.
ISSN: 0732-183X.

DT Article
LA English
SL English

L2 ANSWER 14 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:285475 BIOSIS
DN PREV200100285475
TI Neoadjuvant chemotherapy paxlitaxel+doxorubicin in the treatment
of locally advanced breast cancer: Clinical, mammographic and
pathological
response.
AU Semiglazov, V. F. (1); Bojok, A. A. (1); Arzumanov, A. A. (1);
Klimashevsky, V. F. (1); Pozharissky, K. M. (1)
CS (1) N.N. Petrov Research Institute of Oncology, Saint Petersburg Russia
SO Breast, (February, 2001) Vol. 10, No. Supplement 1, pp. S33-S34. print.
Meeting Info.: 7th International Conference on Adjuvant Therapy of
Primary
Breast Cancer Saint Gallen, Switzerland February 21-24, 2001
ISSN: 0960-9776.

DT Conference
LA English
SL English

L2 ANSWER 15 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:283156 BIOSIS
DN PREV200100283156
TI Treatment of metastatic urothelial cancer in the post-MVAC era.
AU Cohen, Ezra E. W.; Stadler, Walter M. (1)
CS (1) 5841 South Maryland Avenue, Chicago, IL, 60637 USA
SO World Journal of Urology, (April, 2001) Vol. 19, No. 2, pp. 126-132.
print.
ISSN: 0724-4983.

DT Article
LA English
SL English

L2 ANSWER 16 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:281724 BIOSIS
DN PREV200100281724
TI Induction chemotherapy for 465 operable breast cancers: The role of SBR
grading and influence of complete pathological response on survival.
AU Chollet, P. (1); Cure, H. (1); Penault-Llorca, F. (1); Le Bouedec, G.
(1);
Dauplat, J. (1)
CS (1) Centre J. Perrin/Inserm U484, Clermont-Ferrand France
SO Breast, (February, 2001) Vol. 10, No. Supplement 1, pp. S36-S37. print.
Meeting Info.: 7th International Conference on Adjuvant Therapy of
Primary
Breast Cancer Saint Gallen, Switzerland February 21-24, 2001
ISSN: 0960-9776.

DT Conference
LA English

SL English

L2 ANSWER 17 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2001:281653 BIOSIS

DN PREV200100281653

TI The use of anthracyclines and taxanes for adjuvant therapy of breast cancer.

AU Davidson, N. E. (1)

CS (1) Baltimore, MD USA

SO Breast, (February, 2001) Vol. 10, No. Supplement 1, pp. S9. print.
Meeting Info.: 7th International Conference on Adjuvant Therapy of Primary

Breast Cancer Saint Gallen, Switzerland February 21-24, 2001

ISSN: 0960-9776.

DT Conference

LA English

SL English

L2 ANSWER 18 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2001:237244 BIOSIS

DN PREV200100237244

TI Lack of correlation between p53 expression, Bcl-2 expression, apoptosis and ex vivo chemosensitivity in advanced human breast cancer.

AU Rein, Daniel T. (1); Schoendorf, Thomas; Breidenbach, Martina; Janat, Margit M.; Weikelt, Astrid; Goehring, Uwe-Jochen; Becker, Martina; Mallmann, Peter; Kurbacher, Christian M.

CS (1) Department of Gynecology and Obstetrics, University of Cologne, Kerpener Strasse 34, D-50931, Cologne Germany

SO Anticancer Research, (November December, 2000) Vol. 20, No. 6D, pp. 5069-5072. print.

ISSN: 0250-7005.

DT Article

LA English

SL English

L2 ANSWER 19 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2000:539025 BIOSIS

DN PREV200000539025

TI Chemotherapy of metastatic breast cancer.

AU Brun, Bernard (1); Pouillart, Pierre

CS (1) Hopital Pitie-Salpetriere, 47-83, Boulevard de l'Hopital, 75013, Paris

France

SO Bulletin du Cancer (Montrouge), (September, 2000) Vol. 87, No. 9, pp. 643-653. print.

ISSN: 0007-4551.

DT Article

LA French

SL English; French

L2 ANSWER 20 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2000:458422 BIOSIS

DN PREV200000458422

TI Cisplatin plus vinorelbine as a salvage regimen in refractory breast cancer.

AU Gunel, Nazan (1); Akcali, Zafer; Yamac, Deniz; Onuk, Erhan; Yilmaz, Erdal;

Bayram, Orhan; Tekin, Ercument; Coskun, Ugur

CS (1) Planlamacilar Sitesi, 169. Sokak, No:6, Beysukent, Ankara, 06530 Turkey

SO Tumori, (July August, 2000) Vol. 86, No. 4, pp. 283-285. print.
ISSN: 0300-8916.

DT Article
LA English
SL English

L2 ANSWER 21 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:432916 BIOSIS
DN PREV200000432916
TI The role of chemotherapy in prostate cancer. Minireview.
AU Odrazka, K. (1); Vanasek, J.; Vaculikova, M. (1); Stejskal, J.; Filip, S. (1)
CS (1) Department of Oncology and Radiotherapy, Charles University Hospital, 500 05, Hradec Kralove Czech Republic
SO Neoplasma (Bratislava), (2000) Vol. 47, No. 4, pp. 197-203. print.
ISSN: 0028-2685.

DT General Review
LA English
SL English

L2 ANSWER 22 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:414155 BIOSIS
DN PREV200000414155
TI Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer.
AU Bellmunt, J. (1); Guillem, V.; Paz-Ares, L.; Gonzalez-Larriba, J. L.; Carles, J.; Albanell, J.; Tabernero, J. M.; Cortes-Funes, H.; Baselga, J.
CS (1) Hospital General Universitari Vall d'Hebron, P. Vall d'Hebron 119-129, 08035, Barcelona Spain
SO British Journal of Cancer, (August, 2000) Vol. 83, No. 4, pp. S17-S25. print.
ISSN: 0007-0920.

DT General Review
LA English
SL English

L2 ANSWER 23 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:414152 BIOSIS
DN PREV200000414152
TI Advanced bladder and urothelial cancers.
AU Raghavan, D. (1)
CS (1) Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA, 90033 USA
SO British Journal of Cancer, (August, 2000) Vol. 83, No. 4, pp. S1-S6. print.
ISSN: 0007-0920.

DT General Review
LA English
SL English

L2 ANSWER 24 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:355732 BIOSIS
DN PREV200000355732
TI Experience with Caelyx(R) in the treatment of metastatic breast cancer.
AU Moebus, V. (1)
CS (1) Abteilung Gynaekologie, Universitaets-Frauen- und Poliklinik, Prittwitzstrasse 43, D-89075, Ulm Germany
SO Onkologie, (April, 2000) Vol. 23, No. Suppl. 2, pp. 20-25. print.

ISSN: 0378-584X.

DT Article

LA German

SL English; German

L2 ANSWER 25 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2000:355731 BIOSIS

DN PREV200000355731

TI Anthracyclines and Herceptin(R): New treatment option for patients with metastatic breast cancer.

AU Untch, M. (1); Crohns, C.; Kahlert, S.; Hepp, H.

CS (1) Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe Klinikum Grosshadern, Ludwig-Maximilians-Universitaet, Marchioninistrasse 15, D-81377, Muenchen Germany

SO Onkologie, (April, 2000) Vol. 23, No. Suppl. 2, pp. 15-19. print.
ISSN: 0378-584X.

DT Article

LA German

SL English; German

L2 ANSWER 26 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2000:355730 BIOSIS

DN PREV200000355730

TI The role of anthracyclines in the treatment of metastatic breast cancer.

AU Kuhn, W. (1)

CS (1) Frauenklinik und Poliklinik, Klinikum rechts der Isar, Technische Universitaet Muenchen, Ismaninger Strasse 22, D-81675, Muenchen Germany

SO Onkologie, (April, 2000) Vol. 23, No. Suppl. 2, pp. 12-14. print.
ISSN: 0378-584X.

DT Article

LA German

SL English; German

L2 ANSWER 27 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2000:320408 BIOSIS

DN PREV200000320408

TI Introducing taxanes in the adjuvant treatment of breast cancer:
Expectations and reality.

AU Colleoni, M. (1); Orlando, L.; Nole', F.; Goldhirsch, A.

CS (1) International Breast Cancer Study Group, Division of Medical Oncology,

European Institute of Oncology, Via Ripamonti 435, 20141, Milan Italy

SO Breast, (June, 2000) Vol. 9, No. 3, pp. 134-138. print.

ISSN: 0960-9776.

DT General Review

LA English

SL English

L2 ANSWER 28 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2000:261868 BIOSIS

DN PREV200000261868

TI Onycholysis as a complication of systemic chemotherapy: Report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature.

AU Hussain, Sabir; Anderson, Dina N.; Salvatti, Mary Ellen; Adamson, Barbara;

McManus, Margaret; Braverman, Albert S. (1)

CS (1) Health Science Center at Brooklyn, State University of New York, 450 Clarkson Avenue, Brooklyn, NY, 11203-2098 USA

SO Cancer, (May 15, 2000) Vol. 88, No. 10, pp. 2367-2371. print..

ISSN: 0008-543X.
DT Article; General Review
LA English
SL English

L2 ANSWER 29 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:222035 BIOSIS
DN PREV200000222035
TI A unified definition of clinical anthracycline resistance breast cancer.
AU Pivot, X. (1); Asmar, L.; Buzdar, A. U.; Valero, V.; Hortobagyi, G.
CS (1) Centre Antoine Lacassagne, 33 avenue de Vallombrose, 06189, Nice
cedex, 2 France
SO British Journal of Cancer, (Feb., 2000) Vol. 82, No. 3, pp. 529-534.
ISSN: 0007-0920.
DT Article
LA English
SL English

L2 ANSWER 30 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:200012 BIOSIS
DN PREV200000200012
TI Preclinical evaluation of the cardiotoxicity of taxane-anthracycline
combinations using the model of isolated perfused rat heart.
AU Platel, Denis; Pouna, Paul; Bonoron-Adele, Simone; Robert, Jacques (1)
CS (1) 180 Rue de Saint-Genes, Institut Bergonie, 33076, Bordeaux-Cedex
France
SO Toxicology and Applied Pharmacology, (March 1, 2000) Vol. 163, No. 2, pp.
135-140.
ISSN: 0041-008X.
DT Article
LA English
SL English

=> d 12 31-64

L2 ANSWER 31 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:197884 BIOSIS
DN PREV200000197884
TI The effectiveness of present-day chemotherapy in patients with metastatic
breast cancer resistant to anthracycline antibiotics.
AU Moiseyenko, V. M. (1); Orlova, R. V. (1)
CS (1) N.N.Petrov Research Institute of Oncology, Ministry of Health of the
RF, St. Petersburg Russia
SO Voprosy Onkologii (St. Petersburg), (1999) Vol. 45, No. 4, pp. 445-448.
ISSN: 0507-3758.
DT Article
LA Russian
SL English

L2 ANSWER 32 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:158568 BIOSIS
DN PREV200000158568
TI Treatment of liver metastases of breast cancer by chemotherapy without
taxanes.
AU Vosny, E. K. (1); Dobrovolskaya, N. Yu. (1); Goncharova, I. M. (1)
CS (1) Russian Center for Roentgeno-Radiology Research, the Ministry of
Health of the RF, Moscow Russia
SO Voprosy Onkologii (St. Petersburg), (1999) Vol. 45, No. 2, pp. 189-193.
ISSN: 0507-3758.

DT Article
LA Russian
SL English

L2 ANSWER 33 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:127104 BIOSIS
DN PREV200000127104
TI Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
AU Ciardiello, Fortunato (1); Caputo, Rosa; Pomatico, Grazia; De Laurentiis, Michelino; De Placido, Sabino; Bianco, A. Raffaele; Tortora, Giampaolo
CS (1) Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, Via S. Pansini, 5, I-80131, Naples Italy
SO International Journal of Cancer, (March 1, 2000) Vol. 85, No. 5, pp. 710-715.
ISSN: 0020-7136.

DT Article
LA English
SL English

L2 ANSWER 34 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:78669 BIOSIS
DN PREV200000078669
TI Taxanes: An overview of the pharmacokinetics and pharmacodynamics.
AU Vaishampayan, Ulka; Parchment, Ralph E.; Jasti, Bhaskara R.; Hussain, Maha
CS (1) Harper Hospital, 3990 John R Road, 5 Hudson, Detroit, MI USA
SO Urology, (Dec., 1999) Vol. 54, No. 6A SUPPL., pp. 22-29.
ISSN: 0090-4295.

DT General Review
LA English
SL English

L2 ANSWER 35 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:538124 BIOSIS
DN PREV199900538124
TI In vitro sequence dependence for the multitargeted antifolate (MTA, LY231514) combined with other anticancer agents.
AU Schultz, R. M. (1); Dempsey, J. A. (1); Kraus, L. A.; Schmid, S. M.; Calvete, J. A.; Laws, A. L.
CS (1) Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, IN, 46285 USA
SO European Journal of Cancer, (Sept., 1999) Vol. 35, No. SUPPL. 4, pp. S194.
Meeting Info.: ECCO 10: The European Cancer Conference Vienna, Austria September 12-16, 1999 Federation of European Cancer Societies
ISSN: 0959-8049.

DT Conference
LA English

L2 ANSWER 36 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:492322 BIOSIS
DN PREV199900492322
TI Recent advances in adjuvant therapy of breast cancer.
AU Buzdar, Aman U. (1); Hortobagyi, Gabriel N.

CS (1) University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX, 77030 USA
SO Seminars in Oncology, (Aug., 1999) Vol. 26, No. 4 SUPPL. 12, pp. 21-27.
ISSN: 0093-7754.
DT Article; General Review
LA English

L2 ANSWER 37 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:453170 BIOSIS
DN PREV199900453170
TI DNA damage increases sensitivity to Vinca alkaloids and decreases
sensitivity to taxanes through p53-dependent repression of
microtubule-associated protein 41.
AU Zhang, Christine C.; Yang, Jin-Ming; Bash-Babula, Judy; White, Eileen;
Murphy, Maureen; Levine, Arnold J.; Hait, William N. (1)
CS (1) Cancer Institute of New Jersey, 195 Little Albany Street, New
Brunswick, NJ, 08901 USA
SO Cancer Research, (Aug. 1, 1999) Vol. 59, No. 15, pp. 3663-3670.
ISSN: 0008-5472.
DT Article
LA English
SL English

L2 ANSWER 38 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:425312 BIOSIS
DN PREV199900425312
TI Doxorubicin/taxane combinations: Cardiac toxicity and
pharmacokinetics.
AU Sparano, Joseph A. (1)
CS (1) Albert Einstein Comprehensive Cancer Center, Weiler Division-2 South,
Montefiore Medical Center, 1825 Eastchester Rd, Room 52, Bronx, NY, 10461
USA
SO Seminars in Oncology, (June, 1999) Vol. 26, No. 3 SUPPL. 9, pp. 14-19.
ISSN: 0093-7754.
DT Article
LA English

L2 ANSWER 39 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:392820 BIOSIS
DN PREV199900392820
TI Metastatic breast cancer: The role of chemotherapy.
AU Sledge, George W., Jr. (1); Miller, Kathy D.
CS (1) 535 Barnhill Dr, Indiana Cancer Pavilion RT-473, Indianapolis, IN,
46202 USA
SO Seminars in Oncology, (Feb., 1999) Vol. 26, No. 1 SUPPL. 2, pp. 6-10.
Meeting Info.: The Fox Chase Cancer Center and Free University Hospital
Investigators Workshop and Consensus Conference on Paclitaxel St. Thomas,
Virgin Islands, USA March 25-29, 1998 Fox Chase Cancer Center
. ISSN: 0093-7754.
DT Conference
LA English

L2 ANSWER 40 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:242887 BIOSIS
DN PREV199900242887
TI Inhibitory effects of combinations of HER-2/neu antibody and
chemotherapeutic agents used for treatment of human breast cancers.
AU Pegram, Mark; Hsu, Sheree; Lewis, Gail; Pietras, Richard; Beryt,
Malgorzata; Sliwkowski, Mark; Coombs, Daniel; Baly, Deborah; Kabbinavar,
Fairooz; Slamon, Dennis (1)

CS (1) Department of Medicine, Division of Hematology-Oncology, UCLA School of Medicine, 11-934 Factor Building, Los Angeles, CA, 90095 USA
SO Oncogene, (April 1, 1999) Vol. 18, No. 13, pp. 2241-2251.
ISSN: 0950-9232.

DT Article
LA English
SL English

L2 ANSWER 41 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:230549 BIOSIS

DN PREV199900230549

TI 5-Year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.
AU Hudis, C. (1); Fornier, M.; Riccio, L.; Lebwohl, D.; Crown, J.; Gilewski, T.; Surbone, A.; Currie, V.; Seidman, A.; Reichman, B.; Moynahan, M.; Raptis, G.; Sklarin, N.; Theodoulou, M.; Weiselberg, L.; Salvaggio, R.; Panageas, K. S.; Yao, T. J.; Norton, L.

CS (1) Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY, 10021 USA

SO Journal of Clinical Oncology, (April, 1999) Vol. 17, No. 4, pp. 1118-1126.

ISSN: 0732-183X.

DT Article
LA English
SL English

L2 ANSWER 42 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:207237 BIOSIS

DN PREV199900207237

TI The systemic treatment of AIDS-related Kaposi's sarcoma.

AU Schwartsmann, G. (1); Stefani, S.; Villarroel, R. U.

CS (1) Med. Oncol. Unit, Hosp. Clin. Porto Alegre, Rua Ramino Barcelos 2350/3

leste, Porto Alegre, RS Brazil

SO Cancer Treatment Reviews, (Dec., 1998) Vol. 24, No. 6, pp. 415-424.
ISSN: 0305-7372.

DT General Review
LA English

L2 ANSWER 43 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:182064 BIOSIS

DN PREV199900182064

TI DNA damaging agents increase wild type p53, suppress microtubule associated protein 4 (MAP4), sensitize cells to vinca alkaloids and render

cells resistant to taxanes.

AU Zhang, C.; Bash, J. E.; Hait, W. N.

CS Cancer Inst. New Jersey, UMDNJ/RWJMS, New Brunswick, NJ 08901 USA

SO Proceedings of the American Association for Cancer Research Annual Meeting, (March, 1999) Vol. 40, pp. 95-96.

Meeting Info.: 90th Annual Meeting of the American Association for Cancer Research Philadelphia, Pennsylvania, USA April 10-14, 1999 American Association for Cancer Research

. ISSN: 0197-016X.

DT Conference
LA English

L2 ANSWER 44 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 1999:170403 BIOSIS

DN PREV199900170403

TI A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.

AU Polizzi, Donatella; Pratesi, Graziella; Tortoreto, Monica; Supino, Rosanna; Riva, Antonella; Bombardelli, Ezio; Zunino, Franco (1)

CS (1) Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan Italy

SO Cancer Research, (March 1, 1999) Vol. 59, No. 5, pp. 1036-1040.
ISSN: 0008-5472.

DT Article

LA English

L2 ANSWER 45 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 1999:101807 BIOSIS

DN PREV199900101807

TI Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer.

AU Dieras, Veronique (1)

CS (1) Institut Curie, 26 rue Ulm, 75005 Paris Cedex 5 France

SO Seminars in Oncology, (Oct., 1998) Vol. 25, No. 5 SUPPL. 12, pp. 18-22.
ISSN: 0093-7754.

DT Article

LA English

L2 ANSWER 46 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 1998:513450 BIOSIS

DN PREV199800513450

TI Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin.

AU Nieto, Yago (1); Martin, Miguel; Alonso, Jose Luis; Casado, Antonio; Ayala, Francisco; Lopez-Martin, Jose Antonio; Rodriguez-Lescure, Alvaro; Diaz-Rubio, Eduardo

CS (1) Univ. Colorado Health Sci. Cent., Box B190, 4200 East Ninth Ave., Denver, CO 80262 USA

SO Breast Cancer Research and Treatment, (July, 1998) Vol. 50, No. 2, pp. 167-174.
ISSN: 0167-6806.

DT Article

LA English

L2 ANSWER 47 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 1998:238079 BIOSIS

DN PREV199800238079

TI Structure-activity relationship studies of new taxanes as reversal agents for multi-drug resistance in cancer cells.

AU Ojima, Iwao (1); Bounaud, Pierre-Yves (1); Takeuchi, Criag (1); Liang, Catherine (1); Eppich, Simone M.-G. (1); Pera, Paula; Bernacki, Ralph J.

CS (1) Dep. Chem., State Univ. New York at Stony Brook, Stony Brook, NY 11794-3400 USA

SO Abstracts of Papers American Chemical Society, (1998) Vol. 215, No. 1-2, pp. MEDI 12.
Meeting Info.: 215th American Chemical Society National Meeting Dallas, Texas, USA March 29-April 2, 1998 American Chemical Society
. ISSN: 0065-7727.

DT Conference

LA English

L2 ANSWER 48 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 1998:230993 BIOSIS

DN PREV199800230993

TI New developments in cancer treatment with the novel thymidylate synthase

AU inhibitor raltitrexed ('Tomudex.
AU Blackledge, G. (1)
CS (1) Clin. Res. Group, Zeneca Pharm., Mereside, Alderley Park,
Macclesfield, Cheshire SK10 4TG UK
SO British Journal of Cancer, (1998) Vol. 77, No. SUPPL. 2, pp. 29-37.
ISSN: 0007-0920.
DT Article
LA English

L2 ANSWER 49 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1998:126466 BIOSIS
DN PREV199800126466
TI New taxanes as highly efficient reversal agents for multi-drug
resistance in cancer cells.
AU Ojima, Iwao (1); Bounaud, Pierre-Yves; Takeuchi, Craig; Pera, Paula;
Bernacki, Ralph J.
CS (1) Dep. Chem., State Univ. New York Stony Brook, Stony Brook, NY
11794-3400 USA
SO Bioorganic & Medicinal Chemistry Letters, (Jan. 20, 1998) Vol. 8, No. 2,
pp. 189-194.
ISSN: 0960-894X.
DT Article
LA English

L2 ANSWER 50 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1998:80650 BIOSIS
DN PREV199800080650
TI Effects of tubulin-inhibiting agents in human lung and breast cancer cell
lines with different multidrug resistance phenotypes.
AU Van Ark-Otte, Jannette; Samelis, Giorgos; Rubio, Gonzalo; Lopez Saez,
Jose-Bosco; Pinedo, Herbert M.; Giaccone, Giuseppe (1)
CS (1) Dep. Oncol., University Hosp. Vrije Universiteit, De Boelelaan 1117,
HV 1081 Amsterdam Netherlands
SO Oncology Reports, (Jan.-Feb., 1998) Vol. 5, No. 1, pp. 249-255.
ISSN: 1021-335X.
DT Article
LA English

L2 ANSWER 51 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:539671 BIOSIS
DN PREV199799838874
TI Sequence-dependent synergy of taxanes and topoisomerase I
inhibitors in human breast cancer cell lines.
AU Madden, Timothy; Newman, Robert A.; Tran, Hai T.
CS Univ. Texas MD Anderson Cancer Cent., Houston, TX USA
SO Pharmacotherapy, (1997) Vol. 17, No. 5, pp. 1089.
Meeting Info.: Annual Meeting of the American College of Clinical
Pharmacy
Phoenix, Arizona, USA November 9-12, 1997
ISSN: 0277-0008.
DT Conference; Abstract
LA English

L2 ANSWER 52 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:491814 BIOSIS
DN PREV199799791017
TI Drug interactions with the taxanes.
AU Baker, Sharyn D.
CS Inst. Drug Development, Cancer Therapy Res. Cent., 7703 Floyd Cirl Dr.,
McDermott Build., 3rd Floor, San Antonio, TX 78284-6220 USA

- SO Pharmacotherapy, (1997) Vol. 17, No. 5 PART 2, pp. 126S-132S.
ISSN: 0277-0008.
- DT Journal; Article
LA English
- L2 ANSWER 53 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:491813 BIOSIS
DN PREV199799791016
TI Clinical overview of the taxanes.
AU Goldspiel, Barry R.
CS Natl. Institutes Health, 10 Center Dr.-MSC 1196, Build. 10, Room 1N-257,
Bethesda, MD 20892-1196 USA
SO Pharmacotherapy, (1997) Vol. 17, No. 5 PART 2, pp. 110S-125S.
ISSN: 0277-0008.
- DT General Review
LA English
- L2 ANSWER 54 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:261867 BIOSIS
DN PREV199799568470
TI Human pharmacokinetic characterization and in vitro study of the
interaction between doxorubicin and paclitaxel in patients with
breast cancer.
AU Gianni, Luca (1); Vigano, Lucia; Locatelli, Alberta; Capri, Giuseppe;
Giani, Antonio; Tarenzi, Emilia; Bonadonna, Gianni
CS (1) Lab. Clin. Pharmacol., Div. Medical Oncol. A, Istituto Nazionale
Tumori, Via Venezian 1, 20133 Milano Italy
SO Journal of Clinical Oncology, (1997) Vol. 15, No. 5, pp. 1906-1915.
ISSN: 0732-183X.
DT Article
LA English
- L2 ANSWER 55 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:197882 BIOSIS
DN PREV199799497085
TI Synthesis and evaluation of new taxane-based reversal agents.
AU Ojima, Iwao (1); Bounaud, Pierre-Yves (1); Pera, Paula; Veith, Jean M.;
Bernacki, Ralph J.
CS (1) Dep. Chem., State Univ. New York Stony Brook, Stony Brook, NY
11794-3400 USA
SO Abstracts of Papers American Chemical Society, (1997) Vol. 213, No. 1-3,
pp. MEDI 209.
Meeting Info.: 213th National Meeting of the American Chemical Society
San Francisco, California, USA April 13-17, 1997
ISSN: 0065-7727.
DT Conference; Abstract
LA English
- L2 ANSWER 56 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:197881 BIOSIS
DN PREV199799497084
TI New taxanes as highly efficient reversal agents for multi-drug
resistance in cancer cells.
AU Ojima, Iwao (1); Bounaud, Pierre-Yves (1); Takeuchi, Craig (1); Pera,
Paula; Veith, Jean M.; Bernacki, Ralph J.
CS (1) Dep. Chem., State Univ. New York Stony Brook, Stony Brook, NY
11794-3400 USA
SO Abstracts of Papers American Chemical Society, (1997) Vol. 213, No. 1-3,
pp. MEDI 208.

Meeting Info.: 213th National Meeting of the American Chemical Society
San Francisco, California, USA April 13-17, 1997
ISSN: 0065-7727.

DT Conference; Abstract
LA English

L2 ANSWER 57 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:31637 BIOSIS
DN PREV199799338040
TI Chemotherapy and chemo-radiotherapy of advanced pancreatic carcinoma.
AU Mergenthaler, H.-G. (1); Lueftner, D.; Possinger, K.
CS (1) Med. Klinik Poliklinik II, Universitaetsklin. Charite,
Schumannstrasse
20-21, D-10117 Berlin Germany
SO Onkologie, (1996) Vol. 19, No. 4, pp. 308-312.
ISSN: 0378-584X.
DT General Review
LA English
SL English; German

L2 ANSWER 58 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:856 BIOSIS
DN PREV199799300059
TI Management of metastatic bladder cancer.
AU Loehrer, Patrick J., Sr. (1); De Mulder, Pieter H. M.
CS (1) Indiana Univ. Med. Cent., Indianapolis, IN USA
SO Raghavan, D.; Leibel, S. A.; Scher, H. I.; Lange, P.. (1997) pp. 299-305.
Principles and practice of genitourinary oncology.
Publisher: Lippincott-Raven Publishers 227 East Washington Square,
Philadelphia, Pennsylvania 19106, USA.
ISBN: 0-397-51458-1.
DT Book
LA English

L2 ANSWER 59 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1996:465584 BIOSIS
DN PREV199699187940
TI New promising anticancer agents in development: What comes next.
AU Verweij, Jaap
CS Dep. Med. Oncol., Div. Experimental Chemotherapy Pharmacol., Rotterdam
Cancer Inst., Univ. Hosp., Groene Hilledijk 301, 3075 EA Rotterdam
Netherlands
SO Cancer Chemotherapy and Pharmacology, (1996) Vol. 38, No. SUPPL., pp.
S3-S10.
ISSN: 0344-5704.
DT Article
LA English

L2 ANSWER 60 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1996:335607 BIOSIS
DN PREV199699057963
TI Chemotherapy for invasive bladder cancer.
AU Malkowicz, S. Bruce (1); Vaughn, David J.
CS (1) Div. Urology, 1 Rhoads, 3400 Spruce Street, Univ. Pennsylvania Med.
Cent., Philadelphia, PA 19104 USA
SO Urology, (1996) Vol. 47, No. 4, pp. 602-614.
ISSN: 0090-4295.
DT General Review
LA English

L2 ANSWER 61 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1996:271398 BIOSIS
DN PREV199698827527
TI Recurrent breast cancer treated successfully with mitomycin-C and vinblastine after failure of both doxorubicin-containing regimen and paclitaxel: A case report.
AU Sekine, Ikuo; Sasaki, Yasutsuna (1); Fujii, Hirobumi; Ohtsu, Tomoko; Wakita, Hisashi; Igarashi, Tadahiko; Itoh, Kuniaki; Abe, Kaoru
CS (1) Div. Oncol./Hematol., Natl. Cancer Cent. Hosp. E., 6-5-1, Kashiwanoha, Kashiwa, Chiba 277 Japan
SO Tohoku Journal of Experimental Medicine, (1996) Vol. 178, No. 3, pp. 331-337.
ISSN: 0040-8727.
DT Article
LA English

L2 ANSWER 62 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1996:256675 BIOSIS
DN PREV199698812804
TI Combination regimens of fludarabine and ara-C followed by taxanes (docetaxel and paclitaxel) against human leukemia T-cell lines, CEM/0 and CEM/ara-C/7A.
AU Kwock, R.; Nandy, P.; Solorzano, M.; Avramis, V. I.
CS Div. Hema./Oncol., USC Sch. Med., Childrens Hosp. LA, Los Angeles, CA 90027 USA
SO Proceedings of the American Association for Cancer Research Annual Meeting, (1996) Vol. 37, No. 0, pp. 377.
Meeting Info.: 87th Annual Meeting of the American Association for Cancer Research Washington, D.C., USA April 20-24, 1996
ISSN: 0197-016X.
DT Conference
LA English

L2 ANSWER 63 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1996:245235 BIOSIS
DN PREV199698801364
TI The role of taxanes in the treatment of breast cancer.
AU Capri, G.; Tarenzi, E.; Fulfarro, F.; Gianni, L. (1)
CS (1) Inst. Naz. Tumori, Via Venezian 1, 20133 Milano Italy
SO Seminars in Oncology, (1996) Vol. 23, No. 1 SUPPL. 2, pp. 68-75.
ISSN: 0093-7754.
DT General Review
LA English

L2 ANSWER 64 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1995:209103 BIOSIS
DN PREV199598223403
TI In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers.
AU Zoli, Wainer; Flamigni, Alberto; Frassineti, Giovanni Luca; Bajorko, Paola; De Paola, Franca; Milandri, Carlo; Amadori, Dino (1); Gasperi-Campani, Anna
CS (1) Dep. Med. Oncol., G.B. Morgagni-L. Pierantoni Hosp., U.S.L. 38, Viale Forlanini, 47100 Forli Italy
SO Breast Cancer Research and Treatment, (1995) Vol. 34, No. 1, pp. 63-69.
ISSN: 0167-6806.
DT Article

LA English

=> d 12 abs ibib 54,45,38,64,61,17,14,10,5

L2 ANSWER 54 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AB Purpose: We performed a pharmacologic investigation paclitaxel (PTX) infused over 3 hours and bolus doxorubicin (DOX) to assess the role of sequence, interval between drugs, and duration of doxorubicin infusion on paclitaxel and anthracycline plasma disposition. We also explored possible mechanisms of pharmacokinetic interference involving the physiologic role of the multidrug resistance phenotype in anthracycline and taxane biliary excretion. Patients and Methods: Pharmacokinetics was performed in 80 cycles and 36 women with previously untreated metastatic breast cancer. PTX, DOX, and their metabolites 6-alpha-hydroxyl-PTX (6-alpha-OH-PTX) and

doxorubicinol (DOL) were measured by high-pressure liquid chromatography (HPLC). Human breast cancer MCF-7 wild-type (WT) and

resistant (TH) cell lines were cultured in whole human plasma to study

anthracycline retention after treatment with different combinations of

PTX, Cremophor EL (CEL) (PEG35 castor oil; BASF, Parsippany, NJ), and

DOX.

Results: Pharmacokinetic interference between PTX and DOX was responsible for nonlinearity of DOX plasma disposition and increased concentrations

of

DOX and DOL. These effects were PTX dose-dependent, DOX concentration-dependent, and likely a result of interference at the level of liver elimination. In view of the physiologic role of P-glycoproteins (P-gp) in xenobiotic biliary excretion, retention of DOX was assessed in MCF-7 WT and MCF-7 TH cells. Intracellular was significantly higher in MCF-7 WT than MCF-7 TH ($P < .05$). However, concomitant exposure to DOX, PTX, and CEL caused similar DOX retention in both MCF-7 WT and TH cells. Conclusion: PTX, as clinically formulated in CEL, is responsible or a nonlinear disposition of DOX and DOL. Nonlinearity is PTX- and DOX-dependent, and possibly caused by competition for biliary excretion

of

taxanes and anthracyclines mediated by P-gp. Nonlinearity indicates that even minor modifications of dose and infusion duration of DOX and PTX may lead to unpredictable pharmacodynamic consequences. The postulated role of P-gp suggests that CEL is clinically active, and advises caution in designing combinations of PTX with other drugs that

are

substrate for P-gp.

ACCESSION NUMBER: 1997:261867 BIOSIS

DOCUMENT NUMBER: PREV199799568470

TITLE: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.

AUTHOR(S): Gianni, Luca (1); Vigano, Lucia; Locatelli, Alberta; Capri,

Giuseppe; Giani, Antonio; Tarenzi, Emiliana; Bonadonna, Gianni

CORPORATE SOURCE: (1) Lab. Clin. Pharmacol., Div. Medical Oncol. A, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milano Italy

SOURCE: Journal of Clinical Oncology, (1997) Vol. 15, No. 5, pp. 1906-1915.

ISSN: 0732-183X.

DOCUMENT TYPE: Article

LANGUAGE: English

L2 ANSWER 45 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1999:101807 BIOSIS

DOCUMENT NUMBER: PREV199900101807

TITLE: Taxanes in combination with doxorubicin
in the treatment of metastatic breast cancer.

AUTHOR(S): Dieras, Veronique (1)

CORPORATE SOURCE: (1) Institut Curie, 26 rue Ulm, 75005 Paris Cedex 5 France

SOURCE: Seminars in Oncology, (Oct., 1998) Vol. 25, No. 5 SUPPL.
12, pp. 18-22.

ISSN: 0093-7754.

DOCUMENT TYPE: Article

LANGUAGE: English

L2 ANSWER 38 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1999:425312 BIOSIS

DOCUMENT NUMBER: PREV199900425312

TITLE: Doxorubicin/taxane combinations: Cardiac toxicity
and pharmacokinetics.

AUTHOR(S): Sparano, Joseph A. (1)

CORPORATE SOURCE: (1) Albert Einstein Comprehensive Cancer Center, Weiler
Division-2 South, Montefiore Medical Center, 1825
Eastchester Rd, Room 52, Bronx, NY, 10461 USA

SOURCE: Seminars in Oncology, (June, 1999) Vol. 26, No. 3 SUPPL.
9,

pp. 14-19.

ISSN: 0093-7754.

DOCUMENT TYPE: Article

LANGUAGE: English

L2 ANSWER 64 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AB The in vitro activities of taxol and taxotere in comparison with
cisplatin

and doxorubicin were assessed in 30 primary tumor cultures from
human breast cancers. Both taxanes were much more potent than
cisplatin and doxorubicin. Taxotere was 3.1, 296, and 9.6-fold
more cytotoxic than taxol, cisplatin, and doxorubicin
respectively. The cytotoxic activity observed in our experiments confirms
the potential clinical relevance of the two taxanes in the
management of breast cancer.

ACCESSION NUMBER: 1995:209103 BIOSIS

DOCUMENT NUMBER: PREV199598223403

TITLE: In vitro activity of taxol and taxotere in comparison with
doxorubicin and cisplatin on primary cell cultures
of human breast cancers.

AUTHOR(S): Zoli, Wainer; Flamigni, Alberto; Frassineti, Giovanni

Luca;

Bajorko, Paola; De Paola, Franca; Milandri, Carlo;

Amadori,

Dino (1); Gasperi-Campani, Anna

CORPORATE SOURCE: (1) Dep. Med. Oncol., G.B. Morgagni-L. Pierantoni Hosp.,
U.S.L. 38, Viale Forlanini, 47100 Forlì Italy

SOURCE: Breast Cancer Research and Treatment, (1995) Vol. 34, No.
1, pp. 63-69.

ISSN: 0167-6806.

DOCUMENT TYPE: Article

LANGUAGE: English

L2 ANSWER 61 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AB Cross-resistance is one of the chief obstacles in salvage therapy for
refractory breast cancer. Although paclitaxel is one of the most
promising

drugs, it shows a response rate of 30% at most for patients with breast cancer resistant to doxorubicin, and no effective treatments for tumors refractory to both agents have been reported. We describe a 38-year-old woman with recurrent breast cancer, who was treated successfully with mitomycin-C and vinblastine after doxorubicin-based chemotherapy and paclitaxel failed. The combinations of mitomycin-C and microtubule inhibitors including vinca alkaloids and taxanes may have a potential application to refractory breast cancer.

ACCESSION NUMBER: 1996:271398 BIOSIS

DOCUMENT NUMBER: PREV199698827527

TITLE: Recurrent breast cancer treated successfully with mitomycin-C and vinblastine after failure of both doxorubicin-containing regimen and paclitaxel: A case report.

AUTHOR(S): Sekine, Ikuo; Sasaki, Yasutsuna (1); Fujii, Hirobumi; Ohtsu, Tomoko; Wakita, Hisashi; Igarashi, Tadahiko; Itoh, Kuniaki; Abe, Kaoru

CORPORATE SOURCE: (1) Div. Oncol./Hematol., Natl. Cancer Cent. Hosp. E., 6-5-1, Kashiwanoha, Kashiwa, Chiba 277 Japan

SOURCE: Tohoku Journal of Experimental Medicine, (1996) Vol. 178, No. 3, pp. 331-337.
ISSN: 0040-8727.

DOCUMENT TYPE: Article

LANGUAGE: English

L2 ANSWER 17 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:281653 BIOSIS

DOCUMENT NUMBER: PREV200100281653

TITLE: The use of anthracyclines and taxanes for adjuvant therapy of breast cancer.

AUTHOR(S): Davidson, N. E. (1)

CORPORATE SOURCE: (1) Baltimore, MD USA

SOURCE: Breast, (February, 2001) Vol. 10, No. Supplement 1, pp. S9.

print.

Meeting Info.: 7th International Conference on Adjuvant Therapy of Primary Breast Cancer Saint Gallen, Switzerland February 21-24, 2001
ISSN: 0960-9776.

DOCUMENT TYPE: Conference

LANGUAGE: English

SUMMARY LANGUAGE: English

L2 ANSWER 14 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:285475 BIOSIS

DOCUMENT NUMBER: PREV200100285475

TITLE: Neoadjuvant chemotherapy paxlitaxel+doxorubicin in the treatment of locally advanced breast cancer: Clinical, mammographic and pathological response.

AUTHOR(S): Semiglazov, V. F. (1); Bojok, A. A. (1); Arzumanov, A. A. (1); Klimashevsky, V. F. (1); Pozharissky, K. M. (1)

CORPORATE SOURCE: (1) N.N. Petrov Research Institute of Oncology, Saint Petersburg Russia

SOURCE: Breast, (February, 2001) Vol. 10, No. Supplement 1, pp. S33-S34. print.

Meeting Info.: 7th International Conference on Adjuvant Therapy of Primary Breast Cancer Saint Gallen, Switzerland February 21-24, 2001
ISSN: 0960-9776.

DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English

L2 ANSWER 10 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AB The anthracyclines (doxorubicin and epirubicin) and taxanes (paclitaxel and docetaxel) are among the most active agents for the treatment of advanced breast cancer. The efficacy and safety of anthracycline-taxane combinations have been established in this setting. As a consequence, their use in early-stage breast cancer is an area of active investigation. Two general strategies have been pursued - combinations of taxane and anthracycline and sequential use of anthracycline followed by taxane or the reverse. This review summarizes our current knowledge about the adjuvant use of doxorubicin and paclitaxel or docetaxel for breast cancer, focusing on randomized clinical trials of the US cooperative groups as examples of the development process.

ACCESSION NUMBER: 2001:417515 BIOSIS
DOCUMENT NUMBER: PREV200100417515
TITLE: The use of anthracyclines and taxanes for adjuvant therapy of breast cancer.
AUTHOR(S): Davidson, N. E. (1); Wolff, A. C.
CORPORATE SOURCE: (1) Johns Hopkins Oncology Center, 1650 Orleans Street, Room 409, Baltimore, MD, 21231-1000 USA
SOURCE: Breast, (August, 2001) Vol. 10, No. Supplement 3, pp. 90-95. print.
ISSN: 0960-9776.
DOCUMENT TYPE: General Review
LANGUAGE: English
SUMMARY LANGUAGE: English

L2 ANSWER 5 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 2001:476688 BIOSIS
DOCUMENT NUMBER: PREV200100476688
TITLE: Pharmacokinetic profiles of doxorubicin in combination with taxanes.
AUTHOR(S): Holmes, Frankie Ann (1); Rowinsky, Eric Keith
CORPORATE SOURCE: (1) 909 Frostwood Dr, No. 221, Houston, TX, 77024-2305 USA
SOURCE: Seminars in Oncology, (August, 2001) Vol. 28, No. 4 Suppl 12, pp. 8-14. print.
ISSN: 0093-7754.
DOCUMENT TYPE: Article
LANGUAGE: English
SUMMARY LANGUAGE: English

=> d 12 abs ibib 45

L2 ANSWER 45 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1999:101807 BIOSIS
DOCUMENT NUMBER: PREV199900101807
TITLE: Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer.
AUTHOR(S): Dieras, Veronique (1)
CORPORATE SOURCE: (1) Institut Curie, 26 rue Ulm, 75005 Paris Cedex 5 France
SOURCE: Seminars in Oncology, (Oct., 1998) Vol. 25, No. 5 SUPPL. 12, pp. 18-22.
ISSN: 0093-7754.
DOCUMENT TYPE: Article

LANGUAGE: English

=> d 12 abs ibib 38

L2 ANSWER 38 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1999:425312 BIOSIS
DOCUMENT NUMBER: PREV199900425312
TITLE: Doxorubicin/taxane combinations: Cardiac toxicity
and pharmacokinetics.
AUTHOR(S): Sparano, Joseph A. (1)
CORPORATE SOURCE: (1) Albert Einstein Comprehensive Cancer Center, Weiler
Division-2 South, Montefiore Medical Center, 1825
Eastchester Rd, Room 52, Bronx, NY, 10461 USA
SOURCE: Seminars in Oncology, (June, 1999) Vol. 26, No. 3 SUPPL.
9,
pp. 14-19.
ISSN: 0093-7754.
DOCUMENT TYPE: Article
LANGUAGE: English

=> d 12 abs ibib 17

L2 ANSWER 17 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 2001:281653 BIOSIS
DOCUMENT NUMBER: PREV200100281653
TITLE: The use of anthracyclines and taxanes for
adjuvant therapy of breast cancer.
AUTHOR(S): Davidson, N. E. (1)
CORPORATE SOURCE: (1) Baltimore, MD USA
SOURCE: Breast, (February, 2001) Vol. 10, No. Supplement 1, pp.
S9.
print.
Meeting Info.: 7th International Conference on Adjuvant
Therapy of Primary Breast Cancer Saint Gallen, Switzerland
February 21-24, 2001
ISSN: 0960-9776.
DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English

=> d 12 abs ibib 14

L2 ANSWER 14 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 2001:285475 BIOSIS
DOCUMENT NUMBER: PREV200100285475
TITLE: Neoadjuvant chemotherapy paclitaxel+doxorubicin
in the treatment of locally advanced breast cancer:
Clinical, mammographic and pathological response.
AUTHOR(S): Semiglazov, V. F. (1); Bojok, A. A. (1); Arzumanov, A. A.
(1); Klimashevsky, V. F. (1); Pozharissky, K. M. (1)
CORPORATE SOURCE: (1) N.N. Petrov Research Institute of Oncology, Saint
Petersburg Russia
SOURCE: Breast, (February, 2001) Vol. 10, No. Supplement 1, pp.
S33-S34. print.
Meeting Info.: 7th International Conference on Adjuvant
Therapy of Primary Breast Cancer Saint Gallen, Switzerland
February 21-24, 2001

ISSN: 0960-9776.

DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English

=> log y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

| | |
|-------------------------------|----------------------------|
| SINCE FILE
ENTRY
159.87 | TOTAL
SESSION
160.54 |
|-------------------------------|----------------------------|

STN INTERNATIONAL LOGOFF AT 12:06:20 ON 30 JAN 2002